Oncopharmpod

Prostate Ca Updates From ASCO GU 22

Informações:

Synopsis

We discuss the evolution of metastatic prostate cancer treatments leading up to last week's publication of ARASENS. Also, PROPEL and MAGNITUDE hint at an earlier role in therapy of PARP-inhibitors in prostate cancer. Maybe.